Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma.

ABSTRACT:

Abstract

Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy represents a major advance in the treatment of relapsed/refractory multiple myeloma (RRMM). However, the long time span from leukapheresis to actual CAR-T infusion often necessitates bridging therapies. Because of limited knowledge about the effects of bridging on post-CAR-T clinical course and outcomes, the selection of treatment options is challenging. In this multicenter international observational study, we explored the impact of bridging therapy on hematopoietic reconstitution in 158 patients with RRMM treated with B-cell maturation antigen (BCMA)-directed CAR-T therapy. Based on exposure to classical cytotoxic (CTX) chemotherapy, we classified bridging regimens as non-CTX, intermediate CTX (1-2 CTX agents), or in

SUBMITTER: Frenking JH 

PROVIDER: S-EPMC12361772 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature